<DOC>
	<DOCNO>NCT00335738</DOCNO>
	<brief_summary>This phase III trial study vincristine , carboplatin , etoposide see well work compare observation treat patient undergone surgery newly diagnose retinoblastoma . Drugs use chemotherapy , vincristine , carboplatin , etoposide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) surgery may kill tumor cell remain surgery . Sometimes , surgery , additional treatment need tumor progress . In case , observation may sufficient .</brief_summary>
	<brief_title>Vincristine , Carboplatin , Etoposide Observation Only Treating Patients Who Have Undergone Surgery Newly Diagnosed Retinoblastoma</brief_title>
	<detailed_description>OBJECTIVES : I. Prospectively determine prevalence high-risk histopathologic feature , choroidal involvement , optic nerve invasion , scleral anterior segment involvement , patient newly diagnose unilateral retinoblastoma undergone enucleation . II . Demonstrate patient without certain high-risk feature successfully treated enucleation alone estimate event-free survival ( EFS ) ( event define occurrence extraocular metastatic disease ) overall survival ( OS ) . III . Estimate EFS OS patient specific high-risk feature uniformly treat adjuvant chemotherapy comprise vincristine , carboplatin , etoposide . IV . Estimate incidence toxicity associate propose adjuvant chemotherapy regimen . OUTLINE : This prospective , nonrandomized , multicenter study . Patients assign 1 2 group accord presence high-risk histopathologic feature . GROUP 1 ( high-risk feature ) : Patients receive vincristine IV carboplatin IV 1 hour day 1 etoposide IV 1 hour day 1 2 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . GROUP 2 ( high-risk feature ) : Patients undergo observation periodically least 5 year . After completion study treatment , patient group 1 follow periodically least 5 year .</detailed_description>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Newly diagnose unilateral retinoblastoma Underwent enucleation primary therapy within past 5 week Must enroll submit pathology slide within 21 day enucleation Adjuvant chemotherapy must begin within 35 day enucleation Disease without highrisk histopathologic feature Highrisk feature define follow : Posterior uveal invasion ( include choroidal invasion ) Any degree concomitant choroid and/or optic nerve involvement Tumor involve optic nerve posterior lamina cribrosa independent find Scleral invasion Anterior chamber seed Ciliary body infiltration Iris infiltration No evidence extraocular retinoblastoma clinically , CT scan , MRI brain orbit without gadolinium No tumor cut end optic nerve eye enucleate evidenced histologic examination prior study entry No systemic metastasis evidence bone marrow scan , bone scan , additional test study entry Lansky performance status 50100 % Hemoglobin &gt; 8 g/dL Absolute neutrophil count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine adjust accord age follow : No great 0.4 mg/dL ( ≤ 5 month ) No great 0.5 mg/dL ( 6 month 11 month ) No great 0.6 mg/dL ( 1 year23 month ) No great 0.8 mg/dL ( 2 years5 year ) No great 1.0 mg/dL ( 6 years9 year ) No great 1.2 mg/dL ( 10 years12 year ) No great 1.4 mg/dL ( 13 year [ female ] ) No great 1.5 mg/dL ( 13 year 15 year [ male ] ) No great 1.7 mg/dL ( 16 year [ male ] ) Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2.5 time ULN age No prior therapy enucleation No prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>